Methyl-testosteron | 1159-27-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Methyl-testosteron
• 英文别名: 17-Methoxyandrost-4-en-3-one；17-methoxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
• CAS: 1159-27-9；13990-32-4
• 化学式: C₂₀H₃₀O₂
• 分子量: 302.457
• InChiKey: UWXJGQPTBMQNOW-UHFFFAOYSA-N

物化性质

• 沸点：
  414.5±45.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)
• 保留指数：
  2636

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY
  申请人：Lipocine Inc.

  公开号：US20130225544A1

  公开（公告）日：2013-08-29

  The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure wherein R is —C 13 H 25 O or —C 14 H 27 O. One or both of the esters can be present in the pharmaceutical composition. The composition is formulated such that upon single dose administration to a group of human subject, the composition provides a mean serum testosterone C avg t12-t24 that is within about 35% to about 70% of the mean serum testosterone C avg t0-t24 .
• LIPOBALANCED LONG CHAIN TESTOSTERONE PRODRUGS FOR ORAL DELIVERY
  申请人：Lipocine Inc.

  公开号：US20170020893A1

  公开（公告）日：2017-01-26

  The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select lipobalanced testosterone prodrugs and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a lipobalanced testosterone prodrugs and a pharmaceutically acceptable carrier.
• FORMULATIONS OF TESTOSTERONE AND METHODS OF TREATMENT THEREWITH
  申请人：BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US20220387447A1

  公开（公告）日：2022-12-08

  The present disclosure relates to novel pharmaceutical composition for the administration of testosterone or testosterone derivatives using an aqueous nasal administration. The present disclosure also provides methods of treatment of diseases and disorders associated with fear and anxiety, a decrease in libido, or hypogonadism.
• [EN] TREATMENT OF HEPATIC STEATOSIS RELATED OLIGO-OVULATION<br/>[FR] TRAITEMENT DE L'OLIGO-OVULATION ASSOCIÉE À LA STÉATOSE HÉPATIQUE
  申请人：UNIV LEUVEN KATH

  公开号：WO2017072243A1

  公开（公告）日：2017-05-04

  The present invention relates to a method and composition for use in treating a condition that benefits from the reduction of hepatic and/or visceral fat, such as polycystic ovary syndrome in adolescent girls or women of childbearing age, involving the useof spironolactone, pioglitazone and metformin.